Gesynta Pharma’s drug candidates utilize a unique mechanism of action to reduce inflammation and pain. We are currently developing two drug candidates. Vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I. Read more about our drug development projects.
Gesynta Pharma develops pharmaceutical treatments addressing inflammation – a key underlying driver in a spectrum of diseases. The most advanced drug candidate vipoglanstat is currently in development for the treatment of endometriosis – a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Vipoglanstat is a non-hormonal, potentially disease-modifying drug candidate that inhibits the proinflammatory enzyme mPGES-1. In phase I and II clinical trials, the drug candidate has demonstrated a favorable safety profile and beneficial pharmacological properties. A preclinical proof-of-concept study in an advanced disease model of endometriosis shows that vipoglanstat significantly reduces endometrial lesions and has a positive impact on pain-related parameters and well-being. Based on these robust data, Gesynta Pharma aims to shortly initiate a phase II clinical trial of vipoglanstat in patients with endometriosis.
Gesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.